This article is more than 5 years old. Information may no longer be current.
Eyes with macular retinoschisis respond poorly to early ranibizumab injections
Click Here to Manage Email Alerts
Myopic eyes with macular retinoschisis and choroidal neovascularization responded poorly to intravitreal ranibizumab after 3 months of treatment, according to a study from the University of Bern.
More Lucentis (ranibizumab, Genentech) injections were needed in eyes with macular retinoschisis than eyes without macular retinoschisis to gain comparable best corrected visual acuity by 12 months, the study authors said.
A post hoc analysis of 277 patients from the RADIANCE trial assessed the impact of macular retinoschisis on functional outcomes in patients with myopic choroidal neovascularization treated with ranibizumab.
At baseline, macular retinoschisis was present in 25 patients and not present in 252 patients. Mean patient age was 62 years in those with macular retinoschisis and 55 years in those without macular retinoschisis (P < .0001).
Over 12 months, patients with macular retinoschisis at baseline received a mean of 5.8 ranibizumab injections and those without received four injections (P < .0001).
After 3 months of ranibizumab therapy, best corrected visual acuity improved by 2.8 letters in eyes with macular retinoschisis and 12.3 letters in those without macular retinoschisis; the between-group difference was statistically significant (P = .013).
After 12 months of treatment, mean change in BCVA was 7.1 letters in eyes with macular retinoschisis and 14.4 letters in those without macular retinoschisis. Both changes were significant compared with baseline, but the between-group difference was not significant by 12 months. – by Matt Hasson
Disclosure: The authors report no relevant financial disclosures.
Click Here to Manage Email Alerts